Amsterdam, The Netherlands, November 6, 2017 - IOS Press, an international publisher providing content for scientific, technical and medical communities, is proud to announce that it has acquired StemBook, an online open access review of stem cell biology that was launched by the Harvard Stem Cell Institute (HSCI) in collaboration with the MIND Informatics group at Massachusetts General Hospital in 2008. IOS Press will update, develop, expand and relaunch the site in spring 2018 in collaboration with HSCI.
StemBook's mission has been and will remain to provide an interactive nexus and foundational knowledge resource that offers opportunities for learning, interaction, synergy and community building for stem cell and non-specialist researchers across this highly interdisciplinary scientific domain. It will continue to grow and serve the evolving needs of this burgeoning field.
"HSCI launched StemBook as a resource for the growing field of stem cell science and regenerative medicine and is pleased that IOS Press will continue to build and improve upon its legacy," said Brock Reeve, HSCI Executive Director.
Divided into sections that span the gamut from the basic to the translational, StemBook already provides free access to a collection of more than 50 invited, original, peer-reviewed chapters covering a range of topics related to stem cell biology that have been written by top researchers in the field. These chapters are indexed by PubMed and the content is available on the NCBI Bookshelf. StemBook also connects researchers to vetted, centralized collection of new methods and protocols, recent journal articles of interest, forums for the exchange of information, news and commentaries.
"We are pleased to have the opportunity to work with the HSCI and StemBook's distinguished editorial board to strengthen the site, facilitate the flow of new, open access content and help ensure its sustainability," commented IOS Press Founder and Director Einar Fredriksson. "Stembook is an excellent complement to our growing portfolio of journals, particularly our titles in neurodegenerative diseases and cancer research, that report advancements in the field of stem cell research."
###